Iron supplement has strong potential ahead

28th November, 2014

Established in 2010, Solvotrin Therapeutics is seeking EII funding to launch its groundbreaking iron supplement in Europe next year, and in the United States the following year.

Chief executive Pat O’Flynn, a former Ernst & Young Entrepreneur of the Year finalist, said that Solvotrin Therapeutics’ primary focus is on “improving established therapies, making them better and safer, with the added advantage of patent protection linked to a defined market need”.

Outlining...

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

Is now the time for succession planning?

Crown Square campus shaping up to be proud achievement for Rhatigan

Firms in south-west looking to a bright new future